Ajanta Pharma shines on entering into in-licensing agreement with Biocon
Ajanta Pharma is currently trading at Rs. 2777.00, up by 110.55 points or 4.15% from its previous closing of Rs. 2666.45 on the BSE.
The scrip opened at Rs. 2736.20 and has touched a high and low of Rs. 2820.00 and Rs. 2736.20 respectively. So far 29012 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3115.00 on 27-Dec-2024 and a 52 week low of Rs. 2022.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2730.65 and Rs. 2548.10 respectively. The current market cap of the company is Rs. 34854.54 crore.
The promoters holding in the company stood at 66.25%, while Institutions and Non-Institutions held 26.44% and 7.32% respectively.
Ajanta Pharma has entered into an in-licensing agreement with Biocon for Semaglutide, a GLP-1 receptor agonist. Under the agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia.
Semaglutide, the GLP-1 receptor agonist, is to improve glycaemic control in adults. The product patent expires in most of these markets in March 2026. Ajanta plans to commercialize the products after receiving the regulatory approvals, which are expected in late 2026 or early 2027.
Ajanta has been one of the pioneers among Indian companies to build a strong branded generic business with own field force in over 30 countries across Africa, South-East Asia, Central Asia and the Middle East. In these markets, company has presence in a wide range of therapeutic segments like, Cardiology, Antidiabetic, Ophthalmology, Antibiotic, Antimalarial, Pain, Gynaecology, Paediatric and General Health products.
Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.
